#United States #Innovation #biotech #GenScript #Piscataway

GenScript Biotech Corp's Financial Triumph in FY2025

GenScript Biotech Corporation has reported remarkable financial results for the fiscal year 2025, significantly boosting its global presence and operational capabilities. With a strong emphasis on integrated platform strategies, GenScript showcased a robust revenue growth of approximately US$959.5 million—a notable increase of 61.4% compared to the previous year. The gross profit also saw an impressive rise to about US$553.2 million, marking a growth of 103.3%. Notably, the adjusted net profit skyrocketed by 285%, reaching around US$230.3 million.

Sherry Shao, the Rotating CEO of GenScript, highlighted that the past year represented a period of accelerated growth and thorough execution. This success can be attributed to the company's commitment to enhancing its integrated capabilities spanning from gene synthesis and protein engineering to biologics development and innovation in industrial biotechnology. This strong performance indicates a firm demand in the end markets, bolstered by a globally-scaled operating model.

Key Contributors to Growth

The driving forces behind GenScript's exceptional FY2025 results include:

1. Integrated Platform Synergies: The company's successful integration across various technology platforms has led to substantial value capture. The Life Science Group's (LSG) gene-to-protein workflow emerged as a critical growth driver, contributing approximately 65% to LSG's revenue growth in 2025.

2. Global Reach and Diversified Revenue Base: GenScript has successfully expanded its international presence, especially in North America, Europe, and the Asia-Pacific regions. The European sector reported a 29% increase in revenue, maintaining five consecutive years of growth, while the Asia-Pacific region experienced an impressive 33% uptick.

3. Product and Technology Innovation: The continuous advancement in proprietary technologies and product platforms has spurred growth across different applications, reinforcing GenScript's competitive edge in life science research tools, biologics discovery, and industrial biotechnology.

4. Automation and Digitalization: The integration of AI and automation within R&D and manufacturing processes has significantly enhanced operational efficiency. By the end of 2026, it's projected that 60% of global production capacity will be powered by AI-driven automation.

Business Segment Highlights

Each division within GenScript has contributed substantially to overall performance:

• - GenScript Life Science Group (LSG) generated approximately US$522.1 million in revenue, an increase of 14.8% year-on-year, benefiting largely from robust demand from pharmaceutical and biotech collaborators and growth in AI-driven discovery.
• - ProBio emerged as a standout performer, with a staggering revenue growth of 309.1%, amounting to US$388.7 million, thanks to strategic projects in antibody protein development and cell and gene therapy.
• - Bestzyme also made headway with revenues reaching US$58.0 million, bolstered by ongoing advancements in biotechnology.

The total selling and distribution expenses rose by 12.9%, reflecting investments in commercial teams and market expansion, while administrative expenses increased due to capacity expansion and initial site development costs. Research and development expenses grew by 32.4%, underscoring ongoing recruitment and strategic initiative expansion.

Environmental, Social, and Governance (ESG)

GenScript has made strides in enhancing its ESG profile, receiving recognitions such as an upgraded MSCI ESG rating to AA, inclusion in the FTSE4Good Index Series, and an EcoVadis Silver Medal. Such accolades reflect the company’s commitment to responsible growth and operational integrity.

Conclusion and Future Outlook

As GenScript looks towards 2026, it anticipates further growth fueled by increasing demand for integrated biotechnology platforms and advanced therapeutics. The company remains committed to strengthening cross-platform synergies, expanding its global customer base, and leveraging automation within its operations. Based on current projections, GenScript expects:

• - 15%-18% revenue growth for GenScript LSG
• - 20%-25% growth in fee-for-service revenue for ProBio
• - 10%-15% revenue growth for Bestzyme

Founded in 2002 in New Jersey, GenScript Biotech Corporation is dedicated to enhancing human and environmental health through biotechnology, serving over 200,000 customers worldwide and employing more than 5,700 professionals.

About GenScript

GenScript focuses on providing essential building blocks for researchers and entities aiming to pioneer groundbreaking treatments and products. With an aim to support the full innovation lifecycle—from biotechnology research to drug discovery and industrial biotechnology applications—GenScript is steadfast in its mission to 'Make People and Nature Healthier Through Biotechnology'.